EAACI Congress 2025
BackFT01 - Mastocytosis and mast cells diseases
Friday 13 Jun, 12:00 PM -
13:00 PM Glasgow, United Kingdom
Dochart 2
Flash Talks
12:00
Retrospective Evaluation of Patients Diagnosed with Childhood (Cutaneous) Mastocytosis: Türkiye Childhood Mastocytosis Study Group Multicenter Study
12:07
The Socio-Emotional Impact of Indolent Systemic Mastocytosis: Insights From the PRISM Survey
12:14
Prevalence, Risk and Protective Factors of Anaphylactic Reactions in Patients with Mastocytosis: A Single-Center Analysis
12:21
Favorable Benefit-Risk Profile of Avapritinib in Indolent Systemic Mastocytosis Is Maintained After 3 Years of Therapy: Longer-Term Analysis of the PIONEER Study
12:28
Basal serum tryptase: sex- and age-specific reference intervals in the pediatric and adult population
12:35
Besides HαT, β-duplications and tryptase gene deletions are frequent and also modify circulating tryptase levels in a birth cohort
12:42
Unveiling clinical patterns in hereditary alpha tryptasemia among anaphylaxis patients
12:49
Hereditary Alpha Tryptasemia in a Swiss Cohort: Are Symptoms Possibly Linked to Menopause?
12:56
Bruton’s Tyrosine Kinase Inhibitor Attenuates Mast Cell Activation via Both FceRI- and MRGPRX2-Mediated Pathways
